Standard medicine has a metabolic blind spot, and it costs patients decades. By the time fasting glucose crosses the diabetic threshold, insulin resistance has typically been present for ten to fifteen years. The damage accumulates silently: in vascular walls, in adipose tissue, in the pancreatic beta cells that are progressively exhausted by compensatory overproduction. We are catching a fire that has been burning since the first floor.
The problem is not that physicians do not understand insulin resistance. The problem is that the standard annual panel does not measure the right things at the right time. Fasting glucose tells you how the system is performing today, after years of adaptation. It does not tell you what the system has been doing to maintain that result.
"Fasting insulin is the canary in the coal mine. By the time glucose is elevated, the canary has been dead for years."
Clinical observation, metabolic medicine practice
Why Fasting Glucose Is the Wrong Primary Marker
Glucose homeostasis is extraordinarily well-defended. The body will maintain normal fasting glucose through progressively higher insulin output, fat redistribution, hepatic glucose suppression, and a dozen other compensatory mechanisms, for years, sometimes decades, before glucose itself rises out of range. A normal fasting glucose reading in a patient with insulin resistance is not reassurance. It is evidence that the compensation is still working.
When we rely on fasting glucose as our primary metabolic screen, we are measuring the output of a system that has been compensating for the underlying dysfunction. We are not measuring the dysfunction.
What to Measure Instead
This is the direct signal. A fasting insulin above 10 µIU/mL in the context of normal fasting glucose is a red flag. Above 15 µIU/mL is a clear clinical concern. Most labs flag nothing until the patient is overtly diabetic.
The Homeostatic Model Assessment of Insulin Resistance combines fasting glucose and fasting insulin into a single index. A score above 2.0 warrants attention. Above 2.9 indicates clinically significant resistance in most published reference ranges.
A ratio above 2.0 is one of the most reliable surrogate markers for insulin resistance available on a standard lipid panel. Most clinicians calculate it only if prompted. It costs nothing. The numbers are already there.
For patients where early detection matters most, those with family history, visceral adiposity, or unexplained fatigue, a postprandial glucose challenge is far more sensitive than fasting glucose alone. A two-hour reading above 140 mg/dL is abnormal.
The Clinical Consequence of Late Detection
Insulin resistance does not exist in isolation. It drives cardiovascular risk through endothelial dysfunction and dyslipidaemia. It accelerates cognitive decline through impaired neuronal glucose metabolism, now being studied as a contributor to Alzheimer's disease, sometimes described as Type 3 diabetes. It promotes inflammatory signalling, disrupts sex hormone metabolism, and degrades sleep architecture. Catching it early is not about preventing diabetes. It is about preventing the cascade of downstream consequences that begin accumulating long before any glucose marker flags.
What We Do Differently
Every Ultra Healthy Human metabolic workup includes fasting insulin alongside fasting glucose, with HOMA-IR calculated as standard. We add postprandial glucose testing for any patient with a family history of metabolic disease, elevated triglycerides, unexplained fatigue, or central adiposity. For patients already showing early resistance, we track the full picture quarterly, not annually.
The intervention window for insulin resistance is wide and the tools are well-established: targeted nutrition protocols, structured exercise programming, sleep optimisation, and where appropriate, pharmaceutical support. What closes that window is late detection.
Get the full metabolic picture
A standard annual panel tells you very little about where you are heading metabolically. Our expanded workup includes fasting insulin, HOMA-IR, and postprandial glucose: the markers that catch the problem while there is still time to reverse it cleanly.